ErbB3 as a biomarker and therapeutic target for pulmonary arterial hypertension

Through the detection and inhibition of ErbB3 protein, the difficulties in diagnosis and treatment of pulmonary hypertension are solved, effective diagnosis and treatment of pulmonary hypertension is achieved, and the prognosis of patients is significantly improved.

CN115976196BActive Publication Date: 2024-12-06SHENZHEN PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211622353.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-16
Publication Date
2024-12-06
Estimated Expiration
2042-12-16

AI Technical Summary

Technical Problem

The lack of reliable biomarkers of pulmonary arterial hypertension in the prior art has led to difficulties in diagnosis and treatment, and existing treatments cannot reverse the disease, finding new targets and treatments to improve the prevention and treatment of pulmonary arterial hypertension.

Method used

Using ErbB3 protein as a biomarker and target, diagnose and screen by detecting ErbB3 protein levels, and developing ErbB3 inhibitors to inhibit the proliferation of pulmonary artery endothelial cells, using gene knockout and siRNA technology to verify its prevention and treatment of pulmonary artery hypertension. Effect.

Benefits of technology

ErbB3 protein is significantly higher than that of patients with pulmonary hypertension. As a biomarker for diagnosis and screening, ErbB3 inhibitors significantly improve pulmonary hypertension, and their effectiveness in preventing and treating pulmonary hypertension is verified through gene knockout and siRNA technology. Monoclonal antibodies The drug Seribantumab also showed obvious preventive and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004002952350000011
    Figure HDA0004002952350000011
  • Figure HDA0004002952350000012
    Figure HDA0004002952350000012
  • Figure HDA0004002952350000021
    Figure HDA0004002952350000021
Patent Text Reader

Abstract

The present invention discloses the application of ErbB3 as a biomarker and therapeutic target for pulmonary hypertension. Specifically disclosed are the applications of biomarkers and / or substances for detecting the biomarkers in the diagnosis of pulmonary hypertension or the preparation of products for the diagnosis of pulmonary hypertension and in the preparation of drugs for preventing, treating, alleviating or improving pulmonary hypertension. Experiments have shown that knocking out the ErbB3 gene and inhibiting its expression can significantly inhibit the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension and significantly improve hypoxia-induced PH. The present invention further uses siRNA and the monoclonal antibody drug Seribantumab as ErbB3 inhibitors to verify that they have significant preventive and therapeutic effects on pulmonary hypertension. The development of the biomarker ErbB3 and ErbB3 inhibitors for the diagnosis or auxiliary diagnosis of pulmonary hypertension of the present invention has important clinical application value for the prevention and treatment of pulmonary hypertension.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to the application of ErbB3 as a biomarker and therapeutic target for pulmonary hypertension. Background Art

[0002] Pulmonary hypertension (PH) refers to a hemodynamic and pathophysiological state in which the pulmonary artery pressure rises above a certain threshold. Its main characteristics are increased pulmonary vascular resistance and sustained increase in pulmonary vascular pressure, which can eventually lead to right heart failure and death. PH is a highly malignant vascular disease with a low diagnosis rate, and is known as the "cancer of cardiovascular disease." Early detection and timely treatment are crucial to improving the prognosis of PH patients and improving clinical treatment effects. However, there are currently no reliable biomarkers for PH in clinical practice. Therefore, research and development of highly sensitive and specific biomarkers and their detection methods to diagnose or assist in the diagnosis of PH is one of the key issues that need to be urgently addressed in clinical practice. It will be beneficial to the prevention and treatment of PH and has important clinical application value.

[0003] There is no specific drug for pulmonary hypertension. Most of the existing treatment strategies for pulmonary hypertension (prostacyclin drugs, endothelin receptor antagonists and phosphodiesterase-5 inhibitors, etc.) are mainly aimed at improving symptoms and partially improving prognosis, but cannot reverse the disease. With the progress of molecular biology and the etiology of pulmonary hypertension, gene therapy has gradually become the most promising treatment for this disease. Therefore, finding new targets for pulmonary hypertension and developing safe and effective therapeutic drugs that reverse pulmonary vascular remodeling, inhibit proliferation, and repair endothelial function are of great clinical significance for the treatment of pulmonary hypertension. Summary of the invention

[0004] The purpose of the present invention is to provide a biomarker that can be used for diagnosis, auxiliary diagnosis and / or screening of pulmonary hypertension, and / or to provide a therapeutic target for pulmonary hypertension. The technical problems to be solved are not limited to the technical subjects described, and those skilled in the art can clearly understand other technical subjects not mentioned in this article through the following description.

[0005] In order to achieve the above object, the present invention first provides any of the following applications of a biomarker and / or a substance for detecting the biomarker:

[0006] A1) Use in the diagnosis of pulmonary hypertension or in the preparation of a product for the diagnosis of pulmonary hypertension;

[0007] A2) Use in auxiliary diagnosis of pulmonary hypertension or in the preparation of products for auxiliary diagnosis of pulmonary hypertension;

[0008] A3) Use in screening for pulmonary hypertension or in preparing a product for screening for pulmonary hypertension;

[0009] A4) Use in the preparation of drugs for preventing, treating, alleviating or improving pulmonary hypertension;

[0010] A5) Use in the preparation of a drug for preventing, treating, alleviating or improving hypoxic pulmonary hypertension;

[0011] A6) Use in inhibiting the proliferation of pulmonary artery endothelial cells or in preparing an agent for inhibiting the proliferation of pulmonary artery endothelial cells;

[0012] The biomarker is ErbB3 protein.

[0013] Furthermore, the level (content) of the ErbB3 protein in patients with pulmonary hypertension (PH) is significantly higher than that in healthy people. The ErbB3 protein can be used as a biomarker for diagnosis, auxiliary diagnosis or screening of pulmonary hypertension.

[0014] Furthermore, the pulmonary hypertension (PH) may be hypoxic pulmonary hypertension.

[0015] The ErbB3 is a member of the tyrosine kinase receptor family, also known as human epidermal growth factor receptor 3 (HER3), and is a membrane-bound protein.

[0016] Furthermore, the ErbB3 protein may be any of the following:

[0017] F1) a protein whose amino acid sequence is SEQ ID No. 1;

[0018] F2) a protein having more than 80% identity with the protein shown in F1) and having the same function as the protein shown in F1) obtained by substitution and / or deletion and / or addition of amino acid residues of the amino acid sequence shown in SEQ ID No.1;

[0019] F3) A fusion protein having the same function obtained by connecting a tag to the N-terminus and / or C-terminus of F1) or F2).

[0020] The nucleotide sequence of the gene of the ErbB3 protein (ErbB3 gene) is 56080108-56103505 of GenBank Accession No. NC_000012.12 (Update Date 2022-10-30).

[0021] The ErbB3 protein and ErbB3 gene may be of human origin.

[0022] The tags include, but are not limited to, GST (glutathione sulfhydryltransferase) tag protein, His6 tag protein (His-tag), MBP (maltose binding protein) tag protein, Flag tag protein, SUMO tag protein, HA tag protein, Myc tag protein, eGFP (enhanced green fluorescent protein), eCFP (enhanced cyan fluorescent protein), eYFP (enhanced yellow-green fluorescent protein), mCherry (monomeric red fluorescent protein) or AviTag tag protein.

[0023] Herein, identity refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST webpage on the NCBI homepage website. For example, in Advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively and searching to calculate the identity of an amino acid sequence, the value (%) of identity can then be obtained.

[0024] Herein, the 80% or greater identity may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.

[0025] In the above application, the substance for detecting the biomarker may include a substance for detecting the biomarker by enzyme-linked immunosorbent assay, immunofluorescence, radioimmunoassay, co-immunoprecipitation, immunoblotting, high performance liquid chromatography, capillary gel electrophoresis, near infrared spectroscopy, mass spectrometry, immunochemiluminescence, colloidal gold immunoassay, fluorescent immunochromatography, surface plasmon resonance, immuno-PCR or biotin-avidin technology.

[0026] In the above application, the substance for detecting the biomarker may be a reagent for detecting the content of ErbB3 protein (ie, the concentration of ErbB3 protein).

[0027] In the above application, the reagent for detecting the content of ErbB3 protein may include a substance that binds to ErbB3 protein.

[0028] In the above application, the reagent for detecting the content of ErbB3 protein may also include ErbB3 protein.

[0029] In the above application, the substance binding to ErbB3 protein can be an antibody, a polypeptide, a protein or a nucleic acid molecule.

[0030] The antibody may be a monoclonal antibody, a polyclonal antibody, a genetically engineered antibody, or an antibody variable region Fv, a single-chain antibody ScFv, an antigen-binding fragment Fab or Fab', F(ab')2, Fab'-SH or other antibody fragments, and an antibody derivative.

[0031] In the above application, the antibody may be an ErbB3 protein antibody.

[0032] Furthermore, the detection may be to detect the expression level of ErbB3 protein in the sample to be tested by an enzyme-linked immunosorbent assay (ELISA) method.

[0033] The biomarkers of the present invention can be applied to conventional ELISA protein detection experiments.

[0034] The present invention also provides a kit for diagnosis, auxiliary diagnosis or screening of pulmonary arterial hypertension, which may include any reagent described herein for detecting the content of ErbB3 protein.

[0035] Furthermore, the reagent for detecting the content of ErbB3 protein may be an ErbB3 protein antibody.

[0036] Furthermore, the test sample of the kit may be a body fluid sample (such as whole blood, plasma, serum or saliva, etc.) and a tissue sample, but is not limited thereto.

[0037] Furthermore, the kit may also include ErbB3 protein as a standard.

[0038] The various reagent components of the kit may be present in separate containers, or may be pre-combined in whole or in part into a reagent mixture.

[0039] Furthermore, the kit may be a protein immunoassay kit.

[0040] Furthermore, the kit may be an ELISA kit, an immunoblotting detection kit, an immunochromatography detection kit, a flow cytometry analysis kit or an immunohistochemistry detection kit but is not limited thereto.

[0041] Herein, the product may be a reagent, a test kit, a chip or a test paper.

[0042] The present invention also provides any of the following uses of the biomarker as a target:

[0043] B1) Use in the preparation of drugs for preventing, treating, alleviating or improving pulmonary hypertension;

[0044] B2) Use in the preparation of drugs for preventing, treating, alleviating or improving hypoxic pulmonary hypertension;

[0045] B3) Use in inhibiting the proliferation of pulmonary artery endothelial cells or in preparing an agent for inhibiting the proliferation of pulmonary artery endothelial cells.

[0046] The present invention also provides any of the following uses of the ErbB3 inhibitor:

[0047] C1) Use in the preparation of drugs for preventing, treating, alleviating or improving pulmonary hypertension;

[0048] C2) Use in the preparation of drugs for preventing, treating, alleviating or improving hypoxic pulmonary hypertension;

[0049] C3) Use in inhibiting the proliferation of pulmonary artery endothelial cells or in preparing an agent for inhibiting the proliferation of pulmonary artery endothelial cells;

[0050] The ErbB3 inhibitor may be a substance that inhibits ErbB3 gene expression, silences or knocks out ErbB3 gene, and / or a substance that reduces the content and / or activity of ErbB3 protein.

[0051] Furthermore, the inhibition of ErbB3 gene expression, silencing or knocking out the ErbB3 gene can be achieved by gene mutation, gene silencing, gene knockout, gene editing or gene knockdown techniques known to those skilled in the art. For example, RNA interference (RNAi) technology can be used to specifically eliminate or shut down the expression of a specific gene; the tool using gene editing technology can be CRISPR / Cas9 technology, zinc finger nuclease (ZFNs) or transcription activator-like effector nuclease (TALENs) technology, etc., but are not limited thereto.

[0052] The technology of inactivating ErbB3 gene expression or silencing the gene at the post-transcriptional level or translational level by using gene knock-down technology is well known to those skilled in the art. The gene knock-down technology includes RNA interference, Morpholino interference, antisense nucleic acid, ribozyme or dominant negative inhibitory mutation, but is not limited thereto.

[0053] It is well known to those skilled in the art that shRNA or siRNA expressed by viruses (such as lentivirus, adeno-associated virus) can be used to inhibit the expression of ErbB3 gene and silence the ErbB3 gene.

[0054] The ErbB3 inhibitor may be one or more of a nucleic acid molecule, a carbohydrate, a lipid, a small molecule compound, an antibody, a polypeptide, a protein, a gene editing vector, a lentivirus or an adeno-associated virus.

[0055] The nucleic acid molecule may be microRNA, siRNA, shRNA and / or antisense oligonucleotide. Further, the microRNA, siRNA, shRNA and / or antisense oligonucleotide (such as antisense RNA) is used to inhibit the expression of ErbB3 gene.

[0056] The antibody may be an antibody against ErbB3 protein or a functional fragment thereof.

[0057] The siRNA targets and interferes with the expression of ErbB3 gene.

[0058] In the above application, the ErbB3 inhibitor may be any of the following:

[0059] D1) siRNA for ErbB3 gene silencing;

[0060] D2) ErbB3 protein antibody;

[0061] D3) siRNA, the nucleotide sequence of the sense strand of the siRNA may be SEQ ID No. 2, and the nucleotide sequence of the antisense strand may be SEQ ID No. 3;

[0062] D4) ErbB3 monoclonal antibody drug Seribantumab (MM-121).

[0063] The present invention also provides a pharmaceutical composition, which may include the ErbB3 inhibitor, and has at least one of the following uses:

[0064] E1) Prevent, treat, alleviate or improve pulmonary hypertension;

[0065] E2) Prevent, treat, alleviate or improve hypoxic pulmonary hypertension;

[0066] E3) inhibits the proliferation of pulmonary artery endothelial cells.

[0067] Furthermore, the pharmaceutical composition may also include one or more pharmaceutically acceptable carriers.

[0068] The pharmaceutically acceptable carrier may be a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, an adsorption carrier, a surfactant or a lubricant.

[0069] The pulmonary hypertension (PH) described herein may be hypoxic pulmonary hypertension.

[0070] The inhibition of pulmonary artery endothelial cell proliferation described herein may be inhibition of pulmonary artery endothelial cell proliferation caused (induced) by hypoxia.

[0071] The purposes of the above-mentioned applications and methods may be disease diagnosis, disease prognosis and / or disease treatment, and their purposes may also be non-disease diagnosis, non-disease prognosis and non-disease treatment purposes; their direct purpose may be to obtain information on intermediate results of disease diagnosis results, disease prognosis results and / or disease treatment results, and their direct purpose may be non-disease diagnosis, non-disease prognosis and / or non-disease treatment purposes.

[0072] After extensive and in-depth research, the inventor unexpectedly found that the level (content) of ErbB3 protein in patients with pulmonary hypertension (PH) is significantly higher than that in healthy people, and developed a biomarker for diagnosis, auxiliary diagnosis or screening of pulmonary hypertension, and further studied the application of ErbB3 gene and its encoded protein in preventing, treating, alleviating or improving pulmonary hypertension with ErbB3 as the target. The present invention verified that ErbB3 gene knockout can significantly prevent and improve hypoxia-induced PH by using ErbB3 gene knockout mice. The present invention also uses siRNA technology to design siRNA targeting ErbB3 gene as ErbB3 inhibitor, and further verified that knocking out ErbB3 gene and inhibiting its expression can significantly inhibit the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension (and pulmonary artery endothelial cell proliferation is an important factor leading to pulmonary vascular remodeling in pulmonary hypertension), and significantly improve PH. The monoclonal antibody drug Seribantumab (MM-121) was further used as an ErbB3 inhibitor to verify its application in the prevention, treatment, relief or improvement of pulmonary arterial hypertension. The results showed that ErbB3 protein antibodies as ErbB3 inhibitors have obvious preventive and therapeutic effects on pulmonary arterial hypertension.

[0073] In summary, the development of the biomarker ErbB3 and ErbB3 inhibitor for diagnosing or assisting in the diagnosis of pulmonary hypertension in the present invention has important clinical application value for the prevention and treatment of pulmonary hypertension. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] Figure 1 ErbB3 is abnormally highly expressed in the lung tissue of patients with hypoxic pulmonary hypertension. A: ErbB3 protein expression in the lung tissue of patients with hypoxic pulmonary hypertension; B: ErbB3 mRNA expression in the lung tissue of patients with pulmonary hypertension.

[0075] Figure 2The expression of ErbB3 in lung tissue is positively correlated with the progression of PH; the expression of ErbB3 in serum samples is positively correlated with the severity of PH. Among them, AB: ELISA and Kaplan-Meier curves showed that the expression level of ErbB3 in lung tissue of patients with pulmonary hypertension was positively correlated with the progression of PH; CD: The expression level of ErbB3 in serum of patients with pulmonary hypertension was significantly increased, and the correlation analysis of pulmonary artery pressure showed that the expression level of ErbB3 was positively correlated with the severity of PH.

[0076] Figure 3 ErbB3 gene knockout significantly prevents hypoxia-induced PH in mice. A: H&E staining and α-SMA immunofluorescence staining results of lung tissue showed that pulmonary vascular remodeling in hypoxic ErbB3 gene knockout mice was significantly reduced compared with that in hypoxic wild-type mice; BC: Right ventricular systolic pressure and right heart hypertrophy index detection showed that right ventricular systolic pressure and right heart hypertrophy index in hypoxic ErbB3 gene knockout mice were significantly lower than those in hypoxic wild-type mice.

[0077] Figure 4 siRNA interference with ErbB3 inhibits the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension. AB: CCK8 assay detects the effect of knocking down ErbB3 on the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension; C: EdU immunofluorescence chemistry assay results show that knocking down ErbB3 inhibits the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension.

[0078] Figure 5 The preventive and therapeutic effects of ErbB3 monoclonal antibody MM-121 on pulmonary hypertension in rats with hypoxia and Sugen / hypoxia PH. A: MM-121 significantly inhibited the increase of ErbB3 protein level in rat lung tissue caused by hypoxia; B: MM-121 prevented muscularization of rat pulmonary microvessels caused by hypoxia; C: MM-121 significantly reduced the increase of right ventricular systolic pressure and right heart hypertrophy index in rats caused by hypoxia; D: MM-121 treatment improved right ventricular systolic pressure and right heart hypertrophy index in Sugen / hypoxia rats. DETAILED DESCRIPTION

[0079] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0080] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0081] The method for constructing the hypoxia-induced PH model in mice and rats in the following examples is as follows: 180-220 g (about 6-8 weeks old) Sprague-Dawley (SD) rats or 18-22 g (about 4-5 weeks old) wild-type and ErbB3 knockout mice were randomly divided into groups and placed in 10% oxygen for continuous hypoxia feeding for 4 weeks to establish the PH model.

[0082] The method for constructing the Sugen5416 / hypoxia-induced PH model in mice and rats is as follows: a single intraperitoneal injection of 20 mg / kg Sugen5416 was followed by feeding in a hypoxic state for 3 weeks to establish the PH model.

[0083] Example 1. Identification of biomarkers for pulmonary hypertension

[0084] Clinical sample collection: Lung tissue and hematological samples (referred to as PH samples) from patients with hypoxic PH (i.e., patients with hypoxic pulmonary hypertension) and matched healthy control samples were obtained from Wuxi People's Hospital Affiliated to Nanjing Medical University (Wuxi, China). Lung tissue and blood samples of the healthy control group were collected from healthy donors.

[0085] In this example, the following expression detection and analysis was performed on lung tissues of 131 hypoxic PH patients (experimental group) and 62 healthy subjects (control group) and serum samples of 125 PH patients and 72 healthy subjects.

[0086] 1. Western blot experiment

[0087] Lung tissue protein extraction, SDS gel electrophoresis, membrane transfer, blocking, immunoblotting, and development.

[0088] 2. Real-time PCR detection

[0089] Lung tissue RNA extraction, reverse transcription, and quantitative analysis.

[0090] 3. Immunohistochemistry

[0091] Lung tissues were washed with PBS, fixed with 4% paraformaldehyde for 24 hours, embedded in paraffin, sectioned, and stained with ErbB3 antibody.

[0092] 4. ELISA test

[0093] Lung tissue was washed in pre-cooled PBS, weighed, and transferred to a glass homogenizer. Pre-cooled PBS was added at a ratio of 1 g sample to 5 ml PBS, and the mixture was thoroughly ground on ice. The homogenate was ultrasonically broken and centrifuged at 5000×g for 5 minutes. The supernatant was taken for detection by ELISA kit (product of Thermo Scientific, catalog number EHERBB3); the supernatant of serological samples was directly taken for detection.

[0094] The results of the analysis showed that compared with the control group, ErbB3 expression in PH samples was upregulated ( Figure 1 ). Western blot( Figure 1 A, p<0.00001) and Real-time PCR ( Figure 1 (B, p<0.0001) analysis confirmed that ErbB3 protein and gene expression levels were significantly upregulated in lung tissue and pulmonary arteries of PH patients compared with controls. Further immunohistochemical results showed that ErbB3 was highly expressed in the thickened intima of the distal pulmonary artery of PH patients. We then compared the ErbB3 levels of three major human vascular cells isolated from PH patients. We further analyzed the expression of ErbB3 in 131 PH lung tissues and 62 control lung tissues ( Figure 2 Middle A). Kaplan-Meier curve showed that higher ErbB3 levels predicted a poor prognosis in PH patients ( Figure 2 In addition, the expression of ErbB3 in serum samples was significantly positively correlated with the pulmonary artery pressure in PH patients ( Figure 2 These results indicate that ErbB3 is a potential pathogenic protein that promotes the occurrence and development of PH.

[0095] The above results indicate that ErbB3 protein can be used as a biomarker for the diagnosis of pulmonary hypertension.

[0096] The amino acid sequence of ErbB3 protein is

[0097] >AAH02706.1 ERBB3 protein[Homo sapiens]

[0098] MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIV RDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKAF(SEQ ID No.1).

[0099] Example 2: Detection method of ErbB3, a biomarker of pulmonary hypertension

[0100] 1. Sample collection and processing

[0101] 1-1. Sample details and inclusion criteria

[0102] The patient group was selected clinically at 50±5 years old with a mean pulmonary artery pressure of 80±15 mmHg, and the control group was derived from healthy donor lung tissue matched with the patient group in age and gender.

[0103] 1-2. Sample processing

[0104] Lung tissue samples were washed in pre-cooled PBS, weighed, transferred to a glass homogenizer, and fully ground on ice. The homogenate was ultrasonically disrupted and centrifuged at 5000×g for 5 minutes, and the supernatant was collected.

[0105] 2. ELISA method to detect ErbB3 protein content

[0106] The supernatant of lung tissue homogenate was taken for ELISA detection. The ELISA kit (CUSABIO product, catalog number CSB-EL007765HU) was used according to the instructions of the kit. The detection antibody was ErbB3 protein antibody.

[0107] 3. Result determination

[0108] The critical value of ErbB3 for the diagnosis of pulmonary hypertension is 7.6435 ng / mL.

[0109] Example 3: Performance of ErbB3 protein in the diagnosis of pulmonary hypertension

[0110] According to the method described in Example 2, the diagnostic performance of the biomarker (ErbB3 protein) of the present invention for diagnosing pulmonary hypertension was verified. The ErbB3 content in the lung tissues of 131 clinical PH patients and 62 controls was detected, and the ErbB3 content in 125 PH patients and 72 normal serum samples was detected. The results showed that the expression of ErbB3 in lung tissue was positively correlated with the progression of PH (p<0.00001); the expression of ErbB3 in serum samples was positively correlated with the severity of PH (p<0.00001). It is proved that ErbB3 protein can be used as a biomarker for the diagnosis of pulmonary hypertension.

[0111] Example 4: Application of ErbB3 protein in improving pulmonary hypertension and inhibiting proliferation of pulmonary artery endothelial cells

[0112] This example uses ErbB3 knockout mice to verify that ErbB3 protein deficiency can improve hypoxia-induced PH. The specific steps are as follows:

[0113] 1. ErbB3 gene knockout can improve hypoxia-induced PH

[0114] A wild-type mouse group was used as a control. A hypoxia-induced mouse PH model was used to evaluate the development of PH. In the hypoxia-induced PH model, 6-week-old mice were exposed to hypoxia (10% O2) or normoxia (21% O2) for 4 weeks; in the Sugen / hypoxia model, rats / mice (6-8 weeks old) were treated with a single subcutaneous injection of a vascular endothelial growth factor receptor antagonist (SU5416, 20 mg / kg) followed by 3 weeks of hypoxia (10% O2).

[0115] To reflect the severity of PH, we detected hemodynamic parameters, right ventricular hypertrophy index and pulmonary vascular remodeling. First, mice were anesthetized with 10% chloral hydrate (0.3 ml / 100 g), and a 1.2F (mice) or 1.4F (rat) pressure catheter was inserted into the right jugular vein and into the right ventricle to measure the right ventricular systolic pressure and record it with a multi-channel physiological recorder (ADinstruments). The mouse heart was dissected, the atrial tissue was completely removed, the right ventricle was cut along the edge of the ventricular septum, and the blood was dried with filter paper. The weight of the right ventricle (RV), left ventricle (LV) and interventricular septum (S) (LV+S) was weighed respectively, and the right ventricle / (left ventricle+ventricular septum) (RV / (LV+S)) index was calculated. The ex vivo lung tissue was fixed in neutral formaldehyde for 24 hours, then embedded in paraffin, sectioned, and HE staining and α-Smooth muscleactin (α-SMA) staining were used to observe the pulmonary vascular remodeling in HPH. Figure 3) showed that ErbB3 gene knockout could significantly prevent hypoxia-induced PH in mice.

[0116] 2. ErbB3 gene knockout inhibits the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension

[0117] Pulmonary artery endothelial cell proliferation is an important factor leading to pulmonary vascular remodeling in pulmonary hypertension. We isolated pulmonary artery endothelial cells from patients with pulmonary hypertension, constructed and transfected ErbB3 siRNA to knock down the ErbB3 gene, and detected cell viability by CCK8 after 48 hours, and EdU staining experiment to detect cell proliferation. The constructed siRNA sequence is as follows:

[0118] siRNA positive strand: 5'-GCAACAUUGAUGGAUUUGUUU-3' (SEQ ID No. 2),

[0119] siRNA antisense strand: 5'-ACAAAUCCAUCAAUGUUGCUU-3' (SEQ ID No. 3).

[0120] The results showed that the use of ErbB3 knockout (ErbB3 - / - ) mice and control group (ErbB3 + / + ) mice to evaluate the role of ErbB3 in hypoxia-induced PH. - / - The mice did not show abnormal phenotypic changes under physiological conditions. In contrast, after 4 weeks of hypoxia, the thickness of the media of the distal pulmonary artery of the mice was significantly different. Consistent with these morphological changes, the same ErbB3 + / + Compared with mice, ErbB3 - / - After hypoxia exposure, the right ventricular systolic pressure and right heart hypertrophy index of mice were significantly reduced, indicating that ErbB3 plays a key role in the development of hypoxia-induced pulmonary hypertension. CCK8 cell viability and EdU detection found that siRNA knockout of ErbB3 gene can significantly inhibit the proliferation of pulmonary artery endothelial cells in patients with pulmonary hypertension ( Figure 4 ).

[0121] It can be seen that ErbB3 inhibitors (such as siRNA for ErbB3 gene silencing, specifically siRNA with a sense strand nucleotide sequence of 5-'GCAACAUUGAUGGAUUUGUUU-3' (SEQ ID No. 2) and an antisense strand nucleotide sequence of 5-'ACAAAUCCAUCAAUGUUGCUU-3' (SEQ ID No. 3)) have the function of preventing, treating, alleviating or improving hypoxic pulmonary hypertension and inhibiting the proliferation of pulmonary artery endothelial cells. Downregulating ErbB3 expression by siRNA method can inhibit hypoxia-induced pulmonary artery endothelial cell proliferation and significantly improve PH.

[0122] 3. Application of the monoclonal antibody drug Seribantumab (MM-121) as an ErbB3 inhibitor in the prevention, treatment, relief or improvement of pulmonary arterial hypertension

[0123] ErbB3 inhibitors can be substances that inhibit ErbB3 gene expression, silence or knock out ErbB3 genes, or substances that inhibit or reduce ErbB3 protein content and / or activity. ErbB3 protein antibodies, such as ErbB3 monoclonal antibody drug Seribantumab (MM-121), were used to treat PH rats and found that it can prevent or improve pulmonary hypertension. The specific steps are as follows:

[0124] 1. Experimental steps

[0125] 1) Prevention model: Establishment of hypoxic rat PH model: Rats (6-8 weeks old) were exposed to hypoxia (10% O2) or normoxia (21% O2) for 4 weeks, and MM-121 (10 mg / kg) was given intraperitoneally twice a week during the period. Right ventricular systolic pressure and right heart hypertrophy index were measured respectively.

[0126] 2) Treatment model: Sugen / hypoxia rat PH model was established: rats (6-8 weeks old) were injected subcutaneously with a single vascular endothelial growth factor receptor antagonist (SU5416, 20 mg / kg) and then hypoxic (10% O2) for 3 weeks. After the model was successfully established, MM-121 (10 mg / kg) was given by intraperitoneal injection twice a week for 4 weeks. The right ventricular systolic pressure and right heart hypertrophy index were measured respectively.

[0127] 2. Experimental results

[0128] Compared with the control group, the right ventricular systolic pressure and right heart hypertrophy index of rats in the hypoxic ErbB3 monoclonal antibody drug MM-121 treatment group were significantly reduced; the right ventricular systolic pressure and right heart hypertrophy index of Sugen / hypoxic rats after 4 weeks of MM-121 treatment were significantly lower than those of Sugen / hypoxic rats in the control group.

[0129] The results are as follows Figure 5 As shown, ErbB3 monoclonal antibody MM-121 improves pulmonary hypertension in hypoxic and Sugen / hypoxic PH rats, indicating that MM-121 inhibiting ErbB3 has a significant preventive and therapeutic effect on pulmonary hypertension.

[0130] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.

Claims

1. Any of the following uses of a substance for detecting the expression level of ErbB3 protein: A1) Use in the preparation of products for the diagnosis of pulmonary hypertension; A2) Use in the preparation of products for auxiliary diagnosis of pulmonary hypertension; A3) Use in the preparation of a product for screening of pulmonary hypertension.

2. The use according to claim 1, characterized in that: The substances include substances that bind to ErbB3 protein.

3. The use according to claim 2, characterized in that: The substance is an antibody, a polypeptide, a protein or a nucleic acid molecule.

4. The use according to claim 3, characterized in that: The antibody is an ErbB3 protein antibody.

5. Any of the following uses of ErbB3 inhibitors: C1) Use in the preparation of drugs for preventing, treating, alleviating or improving pulmonary hypertension; C2) Use in the preparation of drugs for preventing, treating, alleviating or improving hypoxic pulmonary hypertension; The ErbB3 inhibitor is the following D1) or D2): D1) siRNA for knocking out the ErbB3 gene, wherein the nucleotide sequence of the sense strand of the siRNA is SEQ ID No. 2, and the nucleotide sequence of the antisense strand is SEQ ID No. 3; D2) ErbB3 protein antibody, wherein the ErbB3 protein antibody is the ErbB3 monoclonal antibody drug Seribantumab.